Therapy Detail

Therapy Name PF-03446962
Synonym
Therapy Description

PF-03446962 is a monoclonal antibody that binds and inhibits ALK-1, potentially resulting in decreased tumor angiogenesis and proliferation (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
PF-03446962 PF-03446962 is a monoclonal antibody that binds and inhibits ALK-1, potentially resulting in decreased tumor angiogenesis and proliferation (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable PF-03446962 Phase I Actionable In a Phase I trial, PF-03446962 treatment was deemed safe and resulted in anti-tumor activity in patients with advanced solid tumors, demonstrating a partial response in 6.8% (3/44) and stable disease in 27.3% (12/44) (PMID: 26655846). detail... 26655846
Unknown unknown transitional cell carcinoma not applicable PF-03446962 Phase II Actionable In a Phase II trial, PF-03446962 demonstrated multiple toxicities and limited efficacy in patients with urothelial cancer (PMID: 24566706). 24566706
Unknown unknown non-small cell lung carcinoma not applicable PF-03446962 Phase I Actionable In a Phase I trial, a patient with non-small cell lung carcinoma demonstrated a partial response for 308 days when treated with PF-03446962 (PMID: 26655846). 26655846
Unknown unknown hepatocellular carcinoma not applicable PF-03446962 Phase I Actionable In a Phase I trial, a patient with hepatocellular carcinoma demonstrated a partial response for 44 days when treated with PF-03446962 (PMID: 26655846). 26655846
Unknown unknown clear cell renal cell carcinoma not applicable PF-03446962 Phase I Actionable In a Phase I trial, a patient with renal clear cell carcinoma demonstrated a partial response for 325 days when treated with PF-03446962 (PMID: 26655846). 26655846
Clinical Trial Phase Therapies Title Recruitment Status